AbbVie
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, AbbVie sits in the top decile of US sponsors by registered trial count (#68 of 15,742 sponsors by registered trial count).
AbbVie: 526 sponsored US clinical trials, 113 recruiting.
AbbVie sponsors 526 registered US clinical trials on ClinicalTrials.gov, 113 of them currently recruiting, and 270 completed. 174 of these trials are in Phase 3-4 (later-stage) and 327 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteer, with 15 trials.
Top-decile sponsor footprint
AbbVie ranks in the top decile of sponsors by registered trial count (#68 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
270 of 342 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
526 total, page 5 of 11
A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
NCT06487572
A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants
NCT06477926
A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe
NCT06402513
An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
NCT06439394
An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
NCT06443775
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.
NCT06414798
A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants
NCT06406348
A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants
NCT06399718
A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease
NCT06346288
A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence
NCT06387394
Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder
NCT06256367
A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration
NCT06278766
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
NCT06158958
A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
NCT06218251
A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants
NCT06148181
Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity
NCT05956509
Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting
NCT05956483
A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults
NCT06054425
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
NCT06068868
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
NCT06032546
Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants
NCT06067568
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
NCT06024239
A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants
NCT06009237
A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration
NCT05995366
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
NCT05969223
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
NCT05941442
A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
NCT05940402
Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
NCT05892757
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
NCT05935033
A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
NCT05878067
A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers
NCT05895266
Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers
NCT05909553
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
NCT05771428
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
NCT05760313
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
NCT05785715
A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants
NCT05836506
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
NCT05570006
Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants
NCT05738850
A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants
NCT05686980
A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults
NCT05691699
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
NCT05652205
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
NCT05653986
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
NCT05644977
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05601882
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT05513703
Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants
NCT05556226
Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.
NCT05567029
A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor
NCT05538585
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
NCT05530278
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
NCT05443724
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 208 |
| Phase 2 | 119 |
| Phase 3 | 154 |
| Phase 4 | 20 |
Therapeutic Areas
What is open in the AbbVie pipeline
113 recruiting of 526 indexed (21% open); 270 completed (51%).
Phase mix: 174 late (III/IV) vs 327 early (I/II) (early-phase heavy).
Top condition: Healthy Volunteer (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
AbbVie: open-pipeline peers nationwide
Peers matched on 526 registered trials and 21% open enrollment, not the therapeutic-area sidebar.
AbbVie sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 526 trials (± recruiting share)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 523 trials · 13% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
- Oregon Health and Science University · 546 trials · 17% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
Sponsors near 21% open enrollment (± trial volume)
- Florida State University · 21% recruiting · 219 trials
- Merck Sharp & Dohme · 22% recruiting · 558 trials
- Axsome Therapeutics · 21% recruiting · 28 trials
- GOG Foundation · 21% recruiting · 14 trials
Related
What to do with this AbbVie page
526 registered trials is a research-attention snapshot, not an endorsement of AbbVie or any single study.
- 113 of AbbVie's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Volunteer is the condition AbbVie studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
AbbVie pipeline card: 526 registered trials from official public datasets.Report a data error.